Orphan Drugs - Worldwide Market Outlook to 2023 by Disease Type, Product Type and Geography
DUBLIN, Sept. 14, 2018 /PRNewswire/ --
The "Orphan Drug Market - Forecasts from 2018 to 2023" report has been added to ResearchAndMarkets.com's offering.
The orphan drug market is projected to grow at a CAGR of 10.94% to reach US$285.799 billion in 2023 from US$153.275 billion in 2017.
During the forecast period, prescription sales in the orphan drug sector are projected to grow at twice the rate of the overall prescription market. However, various government authorities encourage to develop and market orphan drugs. The cost incurred during the research and development of orphan drugs is higher when compared with non-orphan drugs.
The orphan drug market is classified into various segments by disease types, indication, and geographical regions.
The oncologic segment of the orphan drug market was the most dominant sector due to a large number of rare cancer form cases found in patients. Oncology segment is expected to maintain the trend and will be the key segment during the period of the next five years.
The global orphan drug market is expanding globally to cure rare diseases and thus expected to grow in all regions. North America is estimated to have a significant market share due to the high number of research and development going on in the region coupled with high medical cost and skilled labor force available in the region.
Key Topics Covered
1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Currency
1.5. Assumptions
1.6. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Secondary Sources
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Porter's Five Force Analysis
4.6. Life Cycle Analysis - Regional Snapshot
4.7. Market Attractiveness
5. ORPHAN DRUG MARKET BY DISEASE TYPE
5.1. Oncologic Disease
5.2. Metabolic Disease
5.3. Hematologic and Immunologic Disease
5.4. Infectious Disease
5.5. Neurologic Disease
5.6. Others
6. ORPHAN DRUG MARKET BY PRODUCT TYPE
6.1. Biological Products
6.2. Non-Biological Products
7. ORPHAN DRUG MARKET BY GEOGRAPHY
7.1. North America
7.2. South America
7.3. Europe
7.4. Middle East and Africa
7.5. Asia Pacific
8. COMPETITIVE INTELLIGENCE
8.1. Investment Analysis
8.2. Recent Investment and Deals
8.3. Strategies of Key Players
9. COMPANY PROFILES
9.1. Bayer
9.2. Amryt Pharma PLC
9.3. Brisol-Myers Squibb Company
9.4. Novartis AG
9.5. Celgene Corporation
9.6. F.Hoffman-La Roche AG
9.7. Pfizer Inc.
9.8. Alexion
9.9. Sanofi
9.10. AbbVie, Inc.
9.11. RegeneRX Biopharmaceuticals, Inc.
9.12. Johnson & Johnson Services, Inc.
9.13. Shire PLC
9.14. Merck & Co. Inc.
9.15. AstraZeneca
For more information about this report visit
https://www.researchandmarkets.com/research/jgrln9/orphan_drugs?w=5
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Share this article